Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,280.00
Bid: 12,280.00
Ask: 12,284.00
Change: -124.00 (-1.00%)
Spread: 4.00 (0.033%)
Open: 12,334.00
High: 12,362.00
Low: 12,270.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: RBS Profit Slips; AstraZeneca Starts 2019 Well

Fri, 26th Apr 2019 07:37

LONDON (Alliance News) - Stock prices in London are set for a slightly higher open on Friday, as Royal Bank of Scotland warned Brexit could affect future growth amid a busy morning for first quarterly earnings. IG futures indicate the FTSE 100 index is to open 5.2 points higher at 7,439.33. The blue chip index closed down 37.62 points, or 0.5% at 7,434.13 on Thursday. In UK corporate news, RBS reported a decreased profit in the first quarter on lower income and warned Brexit could continue to harm the lender's income growth.The government majority owned bank's operating pretax profit in the three months ended March decreased 17% to GBP1.01 billion from GBP1.21 billion the year before. RBS's profit attributable to shareholders slipped 13% to GBP707 million.RBS attributed the decreased quarterly profit to lower income.RBS's first quarter total income fell 7.9% to GBP3.04 billion from GBP3.30 billion year-on-year, with net-interest income declining 5.6% to GBP2.03 billion from GBP2.15 billion.The lender's cost-to-income ratio edged up to 63.4% in the quarter compared to 60.5% the year prior. RBS' CET1 ratio at the end of March was 16.2%, down from 16.4% at the end of the first quarter a year ago. At the end of 2018, RBS's CET1 ratio stood at 16.2%. The bank's net interest margin in the first quarter was 1.89% versus 2.04% in the first quarter of 2018. In the fourth quarter of 2018, RBS's NIM was 1.95%.AstraZeneca reported a strong set of first quarter results, with new medicines helping drive growth in product sales.AstraZeneca's product sales climbed 10% for the first three months of 2019 to USD5.47 billion, with constant currency growth 14%. Revenue was up 6%, or 11% constant currency, to USD5.49 billion.Pretax profit doubled to USD758 million, with reported operating profit rising 58% at actual currency rates to USD1.10 billion and core operating profit up 84% at actual rates to USD1.65 billion.Looking within products, Oncology sales rose 54% to USD1.89 billion, New Cardiovascular, Renal, & Metabolism sales rose 15% to USD1.03 billion, and Respiratory sales climbed 9% to USD1.28 billion.pressure.Emerging markets as a segment posted 14% growth to USD2.00 billion, with Chinese sales up 21%.Looking ahead, AstraZeneca has reiterated all 2019 guidance, including for high single-digit growth in product sales. Advertising giant WPP said it is making good progress, with first quarter revenue up 0.9% at reported currency to GBP3.59 billion. Excluding currency movements, revenue was down 0.6%, and like-for-like it fell 1.3%. Like-for-like revenue minus pass-through costs in North America fell 8.5%, making it WPP's weakest performing region, due to continued losses among automotive, pharmaceutical, and fast-moving consumer goods clients.UK like-for-like revenue less pass-through costs fell 0.9%, slightly worse than the year ago period, while the figure fell 0.3% in Western Continental Europe.WPP's like-for-like revenue less pass-through costs elsewhere rose 2.3%, with strong growth in the Latin America, Central & Eastern Europe, and South East Asia segments. WPP has reiterated guidance for 2019, targeting a fall in like-for-like less pass-through costs revenue of 1.5% to 2.0%. Online takeaway food platform Just Eat reported a 21% rise in orders for the first quarter of 2019 to 61.4 million, with revenue up 28% to GBP227.9 million. Just Eat's UK orders rose 7.3% to 31.9 million, with performance hurt by a strong comparative, unusually warm weather in February, and the Easter break entirely falling in the second quarter.Outside of the UK, orders surged 40%, helped by strong growth in Canada, Italy, Switzerland, and Ireland. Guidance for 2019 is once again reiterated, with Just Eat seeing revenue between GBP1.0 billion and GBP1.1 billion and underlying earnings before interest, tax, depreciation, and amortisation of GBP185 million to GBP205 million. Publisher Pearson reported a 2% rise in first quarter underlying revenue, with operating performance "on track". Sales in North America were up 2%, Core markets by 4%, and Growth markets flat. Pearson has held all 2019 guidance, with adjusted operating profit guided between GBP590 million and GBP640 million. In the FTSE 250, Computacenter said first-quarter revenue and profit were ahead year-on-year, before the "positive" impact of acquisitions. This is above expectations, given a tough comparative year-on-year.The UK saw revenue growth despite a large one-off deal a year prior, while US also achieved revenue growth on a like-for-like basis. Looking ahead, Computacenter is "firmly" on track to meet 2019 expectations, and confidence has increased following the first quarter performance. Insurer Hastings reported a 4% rise in gross written premiums to GBP235.5 million for the first quarter, with live customer policies up 3% to 2.75 million. Net revenue fell 1% to GBP183.1 million. Hastings also confirmed new Chief Financial Officer John Worth will join on May 10. Iron ore pellet maker Ferrexpo's auditor Deloitte has resigned with immediate effect, the company announced, with the company having recently published long-delayed 2018 results amid an investigation into payments to a charity in Ukraine. In the US on Thursday, Wall Street ended mixed, with the Dow Jones Industrial Average closing 0.5% lower, the S&P 500 marginally lower, but the Nasdaq Composite up 0.2%.The UK earnings following a busy season in the US, with Amazon after the US close Thursday reported a rise in first quarter profit, to USD3.56 billion from USD1.63 billion, beating analyst consensus. Revenue climbed 17% to USD59.70 billion.Looking ahead, Amazon has guided for second quarter revenue of USD59.5 billion to USD63.5 billion, potentially beating analyst consensus of USD62.37 billion. Chipmaker Intel beat market expectations for both revenue and profit, with the former broadly flat at USD16.06 billion, though profit fell to USD3.97 billion from USD4.45 billion. However, looking forward, Intel's own expectations of revenue of USD69.0 billion and adjusted earnings of USD4.35 per share are both short of market forecasts of USD71.05 billion and USD4.51 respectively. Earlier Thursday, industrial firm 3M trimmed its guidance for 2019 adjusted earnings, while Windows operating system maker Microsoft and social network Facebook both reported solid results, beating analyst consensus.The Japanese Nikkei 225 index ended down 0.3% Friday. In China, the Shanghai Composite is off 0.8%, while the Hang Seng index in Hong Kong is flat.The economic calendar has UK BBA mortgage approval figures at 0930 BST and US first-quarter GDP at 1330 BST. "We're expecting to learn today the [US] economy expanded at a 2.6% annualized rate in the first quarter, rather better than we expected at the turn of the year. Our initial assumption was 1% to 2%, and above the consensus of 2.3%," said Ian Shepherdson of Pantheon Macroeconomics."In the 10th year of an economic expansion, and especially given the fading push from fiscal easing, a 2.6% growth rate is very respectable." "And note whatever the number prints, it is a pretty good bet actual growth was stronger, because a long-standing seasonal adjustment problem tends to depress reported growth in the first quarter," he added.

More News
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.